Work

Case Report: Safety and efficacy assessment of teclistamab in relapsed/refractory amyloidosis: a case study

Year: 2025

Type: article

Abstract: Systemic light chain amyloidosis (AL) is an uncommon disorder of clonal plasma cells, marked by the creation of amyloid-forming immunoglobulin light chains that result in amyloid fibril formation and deposition, causing dysfunction in multiple organs. There is no established treatment protocol for patients with relapsed or refractory AL. Teclistamab is a bispecific antibody targeting B-cell maturation antigen (BCMA) and is approved for treating relapsed or refractory multiple myeloma (MM). The objective of our study was to report real-world data on the safety and efficacy of teclistamab in patients with relapsed/refractory AL.

Source: Frontiers in Oncology

DOI: 10.3389/fonc.2025.1664171

Authors: Zhe Chen, Zhijian Zhang, Jieni Yu, Leihua Fu, Jiaping Fu, Weiying Feng

Institution: Shaoxing People's Hospital

Language: English

Topic: Amyloidosis: Diagnosis, Treatment, Outcomes

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,801